Amneal Pharmaceuticals

Historical price data

Amneal Pharmaceuticals is a publicly traded, integrated biopharmaceutical company with a 20+ year history focused on expanding access to essential medicines. It operates across three core segments: Complex Generics, Biosciences (biosimilars and injectables), and Specialty branded pharmaceuticals, primarily in CNS and endocrine disorders. The company leverages over 1 million square feet of U.S. manufacturing capacity, has a robust pipeline with 69 pending ANDAs, and is led by its founding Patel brothers, aiming to bring manufacturing of critical medicines back to the United States.

Advanced development and manufacturing capabilities for complex generic formulations, biosimilars, and improved drug products via the 505(b)(2) regulatory pathway, with a focus on difficult-to-make dosage forms and ready-to-use injectables.

14 drugs in pipeline, 9 in Phase 3

Total raised: $725M

Competes with large generic/biosimilar firms like Teva, Viatris, and Sandoz, as well as specialty pharma companies. Amneal differentiates through its deep expertise in complex, difficult-to-manufacture drug products, its integrated U.S. manufacturing footprint, and its diversified three-pillar commercial model spanning Generics, Biosciences, and Specialty medicines.